Patient characteristics at baseline by treatment regimen and by DVT status
| . | DT-PACE n = 192 median . | DCEP-T n = 40 median . | P . | DVT n = 32 median . | No DVT n = 200 median . | P . |
|---|---|---|---|---|---|---|
| Continuous variables | ||||||
| Age in years | 60 | 58 | .39 | 63 | 59 | .01 |
| β2 microglobulin level, mg/dL | 3.65 | 3.00 | .70 | 3.6 | 3.5 | .85 |
| Bone marrow plasmacytosis, % | 40.00 | 43 | .78 | 30 | 40 | .59 |
| C-reactive protein level, mg/dL | 0.76 | 1.04 | .10 | 0.74 | 0.79 | .54 |
| Serum lactic dehydrogenase level, IU/L | 165 | 162 | .66 | 157.50 | 164.00 | .56 |
| Platelet count, × 1000 cells/μL | 226 | 158 | .0005 | 227.00 | 212.50 | .47 |
| Serum M level, g/dL | 1.70 | 0.01 | .0004 | 1.75 | 1.60 | .52 |
| Serum albumin level, mg/dL | 4 | 4 | .92 | 3.9 | 4.00 | .24 |
| Serum creatinine level, mg/dL | 1.0 | 1.04 | .77 | 1.05 | 1.00 | .76 |
| Hemoglobin level, g/dL | 11.40 | 11.40 | .67 | 11.20 | 11.40 | .86 |
| Prior treatment (mo) | 6.00 | 46.00 | < .0001 | 8.00 | 7.00 | .18 |
| Categorical variables | Percent | Percent | P | Percent | Percent | P |
| Male | 65 | 56 | .67 | 62 | 64 | .85 |
| Chromosome 11 | 62 | 24 | .08 | 42 | 23 | .04 |
| Chromosome 13 | 27 | 35 | .40 | 32 | 27 | .67 |
| Any chromosomal abnormalities | 50 | 62 | .26 | 55 | 52 | .84 |
| IgA subtype | 20 | 25 | .50 | 15 | 22 | .64 |
| Central venous catheter | 100 | 100 | 1.00 | 100 | 100 | 1.00 |
| White | 90 | 100 | .05 | 94 | 91 | 1.00 |
| Performance status at least 2 | 10 | 8 | 1.00 | 13 | 14 | 1.00 |
| Prior treatment more than 6 mo ago | 44 | 97 | < .0001 | 50 | 69 | .06 |
| . | DT-PACE n = 192 median . | DCEP-T n = 40 median . | P . | DVT n = 32 median . | No DVT n = 200 median . | P . |
|---|---|---|---|---|---|---|
| Continuous variables | ||||||
| Age in years | 60 | 58 | .39 | 63 | 59 | .01 |
| β2 microglobulin level, mg/dL | 3.65 | 3.00 | .70 | 3.6 | 3.5 | .85 |
| Bone marrow plasmacytosis, % | 40.00 | 43 | .78 | 30 | 40 | .59 |
| C-reactive protein level, mg/dL | 0.76 | 1.04 | .10 | 0.74 | 0.79 | .54 |
| Serum lactic dehydrogenase level, IU/L | 165 | 162 | .66 | 157.50 | 164.00 | .56 |
| Platelet count, × 1000 cells/μL | 226 | 158 | .0005 | 227.00 | 212.50 | .47 |
| Serum M level, g/dL | 1.70 | 0.01 | .0004 | 1.75 | 1.60 | .52 |
| Serum albumin level, mg/dL | 4 | 4 | .92 | 3.9 | 4.00 | .24 |
| Serum creatinine level, mg/dL | 1.0 | 1.04 | .77 | 1.05 | 1.00 | .76 |
| Hemoglobin level, g/dL | 11.40 | 11.40 | .67 | 11.20 | 11.40 | .86 |
| Prior treatment (mo) | 6.00 | 46.00 | < .0001 | 8.00 | 7.00 | .18 |
| Categorical variables | Percent | Percent | P | Percent | Percent | P |
| Male | 65 | 56 | .67 | 62 | 64 | .85 |
| Chromosome 11 | 62 | 24 | .08 | 42 | 23 | .04 |
| Chromosome 13 | 27 | 35 | .40 | 32 | 27 | .67 |
| Any chromosomal abnormalities | 50 | 62 | .26 | 55 | 52 | .84 |
| IgA subtype | 20 | 25 | .50 | 15 | 22 | .64 |
| Central venous catheter | 100 | 100 | 1.00 | 100 | 100 | 1.00 |
| White | 90 | 100 | .05 | 94 | 91 | 1.00 |
| Performance status at least 2 | 10 | 8 | 1.00 | 13 | 14 | 1.00 |
| Prior treatment more than 6 mo ago | 44 | 97 | < .0001 | 50 | 69 | .06 |